StockNews.com Upgrades Abeona Therapeutics (NASDAQ:ABEO) to “Hold”

Abeona Therapeutics (NASDAQ:ABEO) was upgraded by StockNews.com from a “sell” rating to a “hold” rating in a research report issued on Tuesday.

Several other research firms have also recently weighed in on ABEO. HC Wainwright reissued a “buy” rating and set a $15.00 price objective on shares of Abeona Therapeutics in a report on Monday, November 25th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $18.00 target price on shares of Abeona Therapeutics in a research report on Tuesday, October 29th.

Abeona Therapeutics Stock Up 6.5 %

NASDAQ ABEO traded up $0.36 during trading hours on Tuesday, reaching $5.86. 352,384 shares of the company’s stock traded hands, compared to its average volume of 301,177. Abeona Therapeutics has a 52-week low of $3.05 and a 52-week high of $9.01. The company has a debt-to-equity ratio of 0.31, a current ratio of 6.12 and a quick ratio of 6.12. The firm has a 50-day simple moving average of $5.72 and a 200 day simple moving average of $5.74. The firm has a market cap of $254.73 million, a PE ratio of -2.18 and a beta of 1.43.

Hedge Funds Weigh In On Abeona Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of ABEO. Jane Street Group LLC bought a new stake in Abeona Therapeutics in the 3rd quarter valued at $84,000. Charles Schwab Investment Management Inc. bought a new stake in shares of Abeona Therapeutics in the third quarter worth about $151,000. XTX Topco Ltd bought a new stake in shares of Abeona Therapeutics in the third quarter worth about $160,000. JPMorgan Chase & Co. lifted its position in shares of Abeona Therapeutics by 74.2% in the third quarter. JPMorgan Chase & Co. now owns 67,138 shares of the biopharmaceutical company’s stock worth $424,000 after buying an additional 28,606 shares in the last quarter. Finally, GSA Capital Partners LLP boosted its stake in Abeona Therapeutics by 54.3% during the third quarter. GSA Capital Partners LLP now owns 96,092 shares of the biopharmaceutical company’s stock valued at $607,000 after buying an additional 33,831 shares during the last quarter. Institutional investors own 80.56% of the company’s stock.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.